What is T2 Biosystems, Inc. (TTOO)?

T2 Biosystems, Inc. (TTOO) is a stock in the Healthcare sector, Medical - Diagnostics & Research industry. View full analysis on Stocks360.

What is the current price of TTOO?

The current price of TTOO is $0.00. Prices are updated in real time on Stocks360.

What is TTOO's price-to-earnings (PE) ratio?

TTOO's trailing twelve-month PE ratio is -0.00, based on current price and earnings per share data available on Stocks360.

What is TTOO's market capitalization?

TTOO's market capitalization is $19,632.00, placing it in the small-cap tier.

T2 Biosystems, Inc. (TTOO)

Stock analysis · OTC · Healthcare · Medical - Diagnostics & Research

$0.00

Market Cap

$19.63K

PE (TTM)

-0.00

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

8.18

Day Range

$0.00 – $0.01

52-wk Range

$0.00 – $0.05

Avg Volume

N/A

Volume

35.00

T2 Biosystems, Inc. (TTOO) is a publicly traded company in the Healthcare sector. Latest price: $0.00. Market cap $19.63K. Trailing PE -0.00. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-31 · $0.01 2026-10-29 · $0.00 (-93.64%)

Earnings

Most Recent

Nov 13, 2024

EPS $-0.57 vs est. $-0.64

Beat by $0.07

Next Earnings

Nov 13, 2026

EPS estimate $0.00

Proprietary Signals

Signal snapshot temporarily unavailable.

About T2 Biosystems, Inc.

T2 Biosystems, Inc. is an in vitro diagnostics company that develops and commercializes innovative diagnostic solutions for global markets. Its proprietary technology platform enables the rapid detection of pathogens, biomarkers, and other critical abnormalities directly from a wide array of unpurified patient specimens, including whole blood, plasma, serum, saliva, sputum, cerebrospinal fluid, and urine. The company's commercial offerings include the T2Dx Instrument, a compact bench-top system designed to run various diagnostic assays. Its current suite of diagnostic tests features T2Candida, a direct-from-blood test that rapidly identifies bloodstream infections leading to sepsis and candidemia; T2Bacteria, another direct-from-blood assay for detecting bacterial pathogens commonly associated with sepsis; T2Resistance, which targets and identifies genes conferring carbapenem resistance; and the T2SARS-CoV-2 panel, developed to detect the SARS-CoV-2 virus. In addition to its existing products, T2 Biosystems is actively advancing several diagnostic candidates. These include T2Biothreat, aimed at identifying biothreat pathogens; a comprehensive sepsis panel designed to detect bloods…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.00×
P/S (TTM)	0.00×
P/B	-0.00×
P/FCF (TTM)	-0.00×
EV / EBITDA	-0.77×
EV / Sales	4.70×
Earnings Yield	-2740958.24%
Free Cash Flow Yield	-246169.52%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$33.83M
Revenue (TTM)	$7.19M
Net Income (TTM)	-$538.10M
Free Cash Flow (TTM)	-$42.98M
Net Debt	$33.81M
Working Capital	-$30.96M
Gross Margin	-113.58%
Operating Margin	-690.45%
Net Margin	-696.19%
Return on Equity	147.27%
Return on Invested Capital	-230.51%